… for optimal treatment of patients with thyroid cancer. Also, no … the benefit of L-T4 suppressive
treatment and the risk of … specific groups of thyroid cancer patients with a high risk of …

… benefits and risks … benefits of I-131 therapy for ablation, adjuvant treatment, and treatment
of locoregional and/or metastasis of well-differentiated thyroid cancer and considers the risks …

… for patients at low risk of recurrence and death from thyroid cancer. By applying … thyroid
cancer, we will maximize the benefit of aggressive therapy in patients who are likely to benefit …

… benefits and risks of this practice in patients diagnosed with DTC. Aggressive TSH-suppressive
therapy is of little or no benefit … in which the potential benefits of suppression are weighed …

… The incidence of thyroid cancer … thyroid cancer in the United States (15). For these reasons,
distinguishing patients with negligible risks for disease recurrence from those with higher-risk …

… adult patients with thyroid nodules and differentiated thyroid cancer differ substantially from
… benefit, now seem to be acknowledged. As few modifiable risk factors for thyroid cancer have …

… Using a clinical decision-making framework based on what we have previously published
for active surveillance of very low risk thyroid cancers, we examine 3 critical interrelated …

… Still, the lifetime risk for thyroid cancer is approximately 1.1%, and the 5-year survival rate
has risen to 97.8%, because almost 70% of cases are now diagnosed at an early stage, when …

… that thyroid hormone reduces the risk of thyroid cancer, and since it is hard to define which
patients have sufficiently high risk to warrant its use, prophylactic use of thyroid hormone is …

… to different risks of thyroid cancer. We suggest that further studies should focus on distinguishing
clinically relevant thyroid cancer from low risk thyroid cancer and benign thyroid nodules…